In that small study, patients with liver metastases had an inferior response rate compared with patients with lung metastases (8.3% vs 50.0%).6 Four other independent early trials7,8,9,10 have also demonstrated promising clinical activity of various anti-VEGFR agents plus PD-1/PD-L1 blockade in MSS colorectal cancer, but the responses were considerably lower than those in the REGONIVO trial. The gene discussed is CD274; the disease is colorectal cancer.